Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab in Advanced or Recurrent Endometrial Cancer
NCT07652515Phase 4Not yet recruiting
- Sponsor
- GSK
- Start
- Aug 2026
- Primary completion
- Aug 2030
01
Overview
A Phase 4 trial of dostarlimab in endometrial cancer (EC), sponsored by GSK. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
dostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07652515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07652515.